Welcome to our dedicated page for Inspiremd SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InspireMD, Inc. (NSPR) files reports with the U.S. Securities and Exchange Commission as a Nasdaq-listed medical device company focused on the CGuard® Prime carotid stent system and its proprietary MicroNet™ mesh technology. These SEC filings provide detailed information on the company’s financial condition, capital structure, clinical and regulatory milestones, and governance.
Current reports on Form 8-K frequently disclose key events such as quarterly financial results, private placement financings, warrant exercises, and updates to investor presentations. For example, a November 4, 2025 Form 8-K discusses financial and operating results for the quarter ended September 30, 2025, while a July 31, 2025 Form 8-K outlines a securities purchase agreement for a private placement of common stock and pre-funded warrants, as well as the full exercise of a series of warrants.
Filings also document important regulatory and commercial milestones. A June 24, 2025 Form 8-K reports that InspireMD received FDA premarket approval (PMA) for the CGuard Prime Carotid Stent System in the United States, and a July 9, 2025 Form 8-K references a press release announcing the U.S. commercial launch of CGuard® Prime. Other 8-Ks describe changes to the board of directors, including the appointment of independent directors and audit committee chairs, and amendments that specify committee assignments.
On this page, users can review InspireMD’s Forms 8-K and related exhibits, along with other periodic reports when available. Stock Titan adds AI-powered summaries that explain the main points of lengthy filings, highlight material agreements and capital-raising terms, and surface notable disclosures about clinical and regulatory developments. Investors and researchers can use these NSPR filings to understand how InspireMD reports its progress in carotid stenting, manages its capital resources, and addresses the risks and uncertainties outlined in its forward-looking statements.
InspireMD, Inc. director Paul Stuka reported an insider transaction involving 5,073 shares of the company's common stock on 12/09/2025 at a weighted average price of $1.81, with trades executed between $1.80 and $1.81 per share.
After this activity, he reports beneficial ownership of 391,628 shares held directly. A further 444,195 shares are held by Osiris Investment Partners, L.P., where he serves in a managing capacity; he may be deemed to beneficially own these but expressly disclaims beneficial ownership except to the extent of his pecuniary interest, and states that no transaction occurred in those indirect holdings.
InspireMD, Inc. filed a Form S-8 to register an additional 4,723,370 shares of common stock, par value $0.0001 per share, for issuance under its 2021 Equity Compensation Plan. This expands the pool of shares available for grants such as stock options and restricted stock to employees and other eligible participants in the plan. The filing incorporates by reference the company’s latest Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, certain Current Reports on Form 8-K, and other key governance documents, and includes legal opinions and auditor consents supporting the registration.
InspireMD (NSPR) director insider buy: A reporting person serving as a director purchased 13,431 shares of common stock on 11/12/2025 at $1.62 per share.
After the purchase, the filing shows 373,715 shares beneficially owned directly. It also lists 444,195 shares held indirectly through Osiris Investment Partners, L.P.; the filing states the reporting person may be deemed to beneficially own those only to the extent of any pecuniary interest and includes them for informational purposes.
The signature indicates the report was filed by an attorney-in-fact for the reporting person.
InspireMD (NSPR) filed its Q3 2025 10‑Q, highlighting the first U.S. sales of CGuard Prime after FDA PMA approval in June and a July commercial launch. Revenue rose to $2.523 million from $1.810 million a year ago as U.S. direct sales began and international distributor sales grew. Gross profit improved to $864,000 from $414,000, with gross margin up to 34.2%.
Operating investments to build U.S. commercialization drove higher expenses: R&D $3.635 million, S&M $4.392 million, and G&A $5.888 million. Net loss widened to $12.708 million (loss per share $0.17) versus $7.890 million last year.
Liquidity strengthened from financings and warrant exercises. Cash and cash equivalents were $63.403 million at September 30, 2025. The company closed a private placement with roughly $40.1 million in gross proceeds and received $16.9 million net from Series I warrant exercises. Despite this, management disclosed substantial doubt about the ability to continue as a going concern given expected operating losses until commercial profitability. Shares outstanding were 41,919,141 as of September 30, 2025; 42,370,995 as of November 10, 2025.
InspireMD, Inc. filed an 8-K announcing it furnished a press release with financial and operating results and recent highlights for the three and nine months ended September 30, 2025. The materials were provided on November 4, 2025 and relate to performance through Q3 2025.
The company also furnished an updated investor presentation dated November 2025. Both items were submitted under Items 2.02 and 7.01 and are designated as “furnished,” not “filed,” under the Exchange Act. Exhibits include the press release (99.1), the presentation (99.2), and the cover page inline XBRL file (104).
Director Gary S. Roubin received 48,000 restricted shares of InspireMD common stock on 10/07/2025. The shares were issued at $0 and will vest on
InspireMD director Danny L. Dearen reported beneficial ownership of 58,017 shares of the company's common stock, comprised of 2,000 shares purchased on the open market and 56,017 restricted shares that are stated to vest on September 16, 2026 subject to continued service, with a provision that unvested shares will fully vest if he is not reelected or not nominated for reelection at the 2026 annual meeting. The filing also shows options to purchase 28,206 shares of common stock at an exercise price of $2.41. The option entry lists an exercisable date of 09/16/2035 in the table while the explanation states the options vest on 09/16/2026, creating an inconsistency in exercisability timing in the filing.
Thomas J. Kester reported transactions in InspireMD, Inc. (NSPR) on a Form 4 filed 09/17/2025. The filing shows a grant of 37,815 shares of common stock on 09/15/2025 for services rendered as a director, increasing his beneficial ownership to 458,573 shares. The report also discloses an option grant of 19,041 options with a $2.38 exercise price, exercisable 09/15/2025 and expiring 09/15/2027, covering 19,041 underlying common shares. The explanatory note states these equity awards were granted in 2025 prior to Mr. Kester's resignation as a director, effective 09/16/2025. The form is signed 09/17/2025.
FAQ
What is the current stock price of Inspiremd (NSPR)?
What is the market cap of Inspiremd (NSPR)?
